Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer

Phase 2 Terminated 11 enrolled Washington University School of Medicine CTI BioPharma · collab

NaSingle-groupOpen-labelTreatment

Summary

The investigators propose to assess the efficacy, progression-free survival, and adverse events of pacritinib in patients with refractory colorectal cancer.

Timeline

Start: 2015-09-22
Primary completion: 2016-03-31
Completion: 2016-10-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pacritinib	Small molecule	200 mg	Oral

Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer

Summary

Timeline

Drugs

Indications